VXRT Vaxart Covid-19, Uptrend and Price Target
VXA-CoV2-1, Vaxart's experimental treatment for Covid-19 is unique in that it's a pill, not an injection.
A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates.
On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies in trial participants, which makes it less efficient than traditional COVID-19 injections.
On 6/11/2021 Piper Sandler brokerage Initiated Coverage with Overweight rating and a Price Target of $18.00
From a technical analysis point of view, the stock looks in an uptrend.
A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates.
On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies in trial participants, which makes it less efficient than traditional COVID-19 injections.
On 6/11/2021 Piper Sandler brokerage Initiated Coverage with Overweight rating and a Price Target of $18.00
From a technical analysis point of view, the stock looks in an uptrend.
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880